Edition:
United Kingdom

People: Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

4.63USD
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
$4.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,640
52-wk High
$7.99
52-wk Low
$3.46

Gold, Mitchell 

Dr. Mitchell H. Gold, M.D. is Executive Chairman of the Board, Chief Executive Officer of the company. Mitchell H. Gold, M.D. has served as our executive chairman, chief executive officer and a member of our board of directors since the completion of the Merger in July 2017 and previously served as Private Alpine’s chief executive officer since June 2016 and as Private Alpine’s executive chairman and member of Private Alpine’s board of directors since January 2015. Prior to co-founding Private Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012, Dr. Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000, Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold is currently a Managing Partner at Alpine BioVentures. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin.

Basic Compensation

Total Annual Compensation, USD 300,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,059,380
Fiscal Year Total, USD 2,359,380

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --